NCT06556108View on ClinicalTrials.gov

ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

January 30, 2025

Study Completion Date

January 30, 2026

Conditions
Advanced Solid Tumors
Interventions
BIOLOGICAL

ALPP CAR-T cells

T cells genetically engineered with a CAR targeting ALPP (ALPP CAR) that display specific reactivity against ALPP target cells

DRUG

Fludarabine

Part of the non-myeloablative lymphocyte-depleting preparative regimen.

DRUG

Cyclophosphamide

Part of the non-myeloablative lymphocyte-depleting preparative regimen.

Trial Locations (1)

400037

RECRUITING

Department of Hematology, Xinqiao Hospital, Chongqing

All Listed Sponsors
lead

Xinqiao Hospital of Chongqing

OTHER